Iovance Biotherapeutics Stock Forecast, Price & News

-0.58 (-1.89 %)
(As of 04/20/2021 12:00 AM ET)
Today's Range
Now: $30.17
50-Day Range
MA: $31.86
52-Week Range
Now: $30.17
Volume2.01 million shs
Average Volume1.75 million shs
Market Capitalization$4.43 billion
P/E RatioN/A
Dividend YieldN/A
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Iovance Biotherapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:IOVA
Phone(650) 260-7120
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$2.37 per share


Net Income$-197,560,000.00


Market Cap$4.43 billion
Next Earnings Date5/4/2021 (Estimated)


IOVA, LSCC, WIT and GSX among premarket gainers
April 18, 2021 |
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 3.8%
March 29, 2021 |
Analysts Say ‘Buy the Pullback’ in These 3 Stocks
March 22, 2021 |
Revisiting Iovance Biotherapeutics After The Dip
March 17, 2021 |
IOVA Crosses Below Key Moving Average Level
February 25, 2021 |
IOVA Mar 2021 65.000 call
December 26, 2020 |
IOVA Jan 2021 60.000 call
December 25, 2020 |
IOVA Jan 2021 45.000 put
December 25, 2020 |
See More Headlines


Overall MarketRank

1.66 out of 5 stars

Medical Sector

325th out of 2,018 stocks

Biological Products, Except Diagnostic Industry

39th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-0.58 (-1.89 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

Is Iovance Biotherapeutics a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Iovance Biotherapeutics stock.
View analyst ratings for Iovance Biotherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Iovance Biotherapeutics?

Wall Street analysts have given Iovance Biotherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Iovance Biotherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Iovance Biotherapeutics?

Iovance Biotherapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 21,320,000 shares, an increase of 43.3% from the March 15th total of 14,880,000 shares. Based on an average daily volume of 1,780,000 shares, the days-to-cover ratio is presently 12.0 days.
View Iovance Biotherapeutics' Short Interest

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Iovance Biotherapeutics

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings results on Wednesday, February, 24th. The biotechnology company reported ($0.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.03.
View Iovance Biotherapeutics' earnings history

How has Iovance Biotherapeutics' stock price been impacted by Coronavirus (COVID-19)?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IOVA shares have increased by 2.0% and is now trading at $30.17.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IOVA?

11 brokers have issued 12-month price targets for Iovance Biotherapeutics' stock. Their forecasts range from $35.00 to $65.00. On average, they anticipate Iovance Biotherapeutics' share price to reach $50.50 in the next year. This suggests a possible upside of 67.4% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:
  • Maria Fardis, President, Chief Executive Officer & Director
  • Jean-Marc Bellemin, Chief Financial Officer & Treasurer
  • Friedrich Graf Finckenstein, Chief Medical Officer
  • Michael C. Swartzburg, Chief Accounting Officer & Vice President-Finance
  • Sara Pellegrino, VP-Investor Relations & Public Relations

Who are some of Iovance Biotherapeutics' key competitors?

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Midwest Bank Trust Division (0.02%), Carnegie Capital Asset Management LLC (0.02%), Phoenix Wealth Advisors (0.01%) and Pacer Advisors Inc. (0.00%).
View institutional ownership trends for Iovance Biotherapeutics

Which major investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Carnegie Capital Asset Management LLC, and Pacer Advisors Inc..
View insider buying and selling activity for Iovance Biotherapeutics
or view top insider-selling stocks.

Which major investors are buying Iovance Biotherapeutics stock?

IOVA stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, and Phoenix Wealth Advisors.
View insider buying and selling activity for Iovance Biotherapeutics
or or view top insider-buying stocks.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $30.17.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics has a market capitalization of $4.43 billion. The biotechnology company earns $-197,560,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

Iovance Biotherapeutics employs 148 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is

Where are Iovance Biotherapeutics' headquarters?

Iovance Biotherapeutics is headquartered at 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at (650) 260-7120 or via email at [email protected]

This page was last updated on 4/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.